Merck, Inc.
π΅πPhilippines
A Study of the Efficacy and Tolerance of Remicade in the Treatment of Active Ankylosing Spondylitis (Study P04042)(COMPLETED)
Phase 4
Completed
- Conditions
- Spondylitis, Ankylosing
- Interventions
- Biological: Infliximab
- First Posted Date
- 2008-10-24
- Last Posted Date
- 2017-05-11
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 42
- Registration Number
- NCT00779012
A Study to Evaluate the Safety and Efficacy of Caelyx in Combination With Carboplatin in Patients With Ovarian Cancer Recurrent Within Six to Twelve Months After Initial Carboplatin and Paclitaxel Chemotherapy (P03625)
Phase 2
Completed
- Conditions
- Ovarian Neoplasms
- Interventions
- First Posted Date
- 2008-10-24
- Last Posted Date
- 2017-05-15
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 58
- Registration Number
- NCT00780039
A Study to Test the Performance of the CogState Computerized Neuropsychological Battery in Patients With Alzheimer's Disease (0000-086)(COMPLETED)
Phase 1
Completed
- Conditions
- Alzheimer's Disease
- Interventions
- First Posted Date
- 2008-10-22
- Last Posted Date
- 2015-08-25
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 106
- Registration Number
- NCT00777608
Bicalutamide and Ridaforolimus in Men With Prostate Cancer (MK-8669-002)
Phase 2
Completed
- Conditions
- Prostate Cancer
- Interventions
- First Posted Date
- 2008-10-22
- Last Posted Date
- 2015-08-19
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 22
- Registration Number
- NCT00777959
Study of Vorinostat (MK0683), an Histone Deacetylase (HDAC) Inhibitor in Combination With Bortezomib in Patients With Relapsed or Refractory Multiple Myeloma (MK-0683-095)
Phase 2
Completed
- Conditions
- Relapsed or Refractory Multiple Myeloma
- Interventions
- First Posted Date
- 2008-10-16
- Last Posted Date
- 2021-04-01
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 143
- Registration Number
- NCT00773838
Study of Vorinostat (MK-0683) or Placebo, in Combination With Bortezomib in Participants With Multiple Myeloma (MK-0683-088 AMN)
Phase 3
Completed
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2008-10-16
- Last Posted Date
- 2021-04-30
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 637
- Registration Number
- NCT00773747
A Study to Evaluate the Effect of Analgesics on a Walking Model of Knee Pain (0000-105)(COMPLETED)
- First Posted Date
- 2008-10-15
- Last Posted Date
- 2015-11-20
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 22
- Registration Number
- NCT00772967
Vorinostat (MK-0683) Phase I Study in Cutaneous T-Cell Lymphoma (CTCL) Patients (MK-0683-089 EXT1)
- First Posted Date
- 2008-10-13
- Last Posted Date
- 2015-04-21
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 10
- Registration Number
- NCT00771472
Clinical Trial to Study the Safety and Effectiveness of MK0826 and Other Antibiotic Therapy in Patients With Complicated Urinary Tract Infection (0826-054)
Phase 3
Terminated
- Conditions
- Urinary Tract Infections
- Interventions
- Drug: MK0826 (ertapenem)
- First Posted Date
- 2008-10-13
- Last Posted Date
- 2017-03-21
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 6
- Registration Number
- NCT00771316
A Study of MK-3009 in Japanese Patients With Skin or Blood Stream Infections Caused by Methicillin-resistant Staphylococcus Aureus (MK-3009-002)
Phase 3
Completed
- Conditions
- Staphylococcal Infection
- Interventions
- First Posted Date
- 2008-10-10
- Last Posted Date
- 2017-03-24
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 122
- Registration Number
- NCT00770341
Β© Copyright 2025. All Rights Reserved by MedPath